<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02291367</url>
  </required_header>
  <id_info>
    <org_study_id>BA085908801</org_study_id>
    <nct_id>NCT02291367</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of Duloxetine Delayed-Release Capsules 60 mg Under Fasting Condition</brief_title>
  <official_title>Single Dose Crossover Comparative Bioavailability Study of Duloxetine Delayed-Release Capsules 60 mg in Healthy Adult Human Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study were to compare the relative bioavailability of Duloxetine HCl delayed release
      capsule 60 mg with that of 'CYMBALTA®' delayed release capsule 60 mg (Duloxetine HCl delayed
      release capsule 60 mg) in healthy, adult, human subjects under fasting conditions and to
      monitor safety of subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open label, randomized, two period, two treatment, two sequence, crossover, balanced, single
      dose comparative oral bioavailability study in healthy, adult, human subjects under fasting
      conditions
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under curve (AUC)</measure>
    <time_frame>1.0, 2.0,3.0, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 9.0, 10.0, 11.0, 12.0, 24.0, 36.0, 48.0,60.0 and 72.0 hours post dose</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Duloxetine Delayed-Release Capsules, 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cymbalta</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cymbalta® 60 mg capsule of Eli Lilly and Company</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>Duloxetine Delayed-Release Capsules 60 mg</description>
    <arm_group_label>Duloxetine Delayed-Release Capsules, 60 mg</arm_group_label>
    <other_name>Cymbalta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cymbalta®</intervention_name>
    <description>60 mg capsule of Eli Lilly and Company</description>
    <arm_group_label>Cymbalta</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Be healthy human between 18 and 45 years

          2. Screened within 21 days prior to administration of first dose of study drug

          3. Having a BMI between 18.5 and 24.9 weight in kg/ height2 in meter

          4. Be able to communicate effectively with study personnel

          5. Be able to give Written informed consent to participate in the study If subject is a
             female volunteer and

          6. is of child bearing potential practicing an acceptable method of birth control for the
             duration of the study as judged by the investigator(s), such as condoms, foams,
             jellies, diaphragm, intrauterine device (IUD), or abstinence.

          7. is postmenopausal for at least 1 year.

          8. is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or
             hysterectomy has been performed on the subject).

        Exclusion Criteria:

          1. History of allergic responses to Duloxetine or other related drugs.

          2. Have significant diseases or clinically significant abnormal findings during
             screening, medical history, physical examination, laboratory evaluations, ECG &amp; X-ray
             recordings.

          3. Any disease or condition which might compromise the haemopoeitic, gastrointestinal,
             renal, hepatic, cardiovascular, respiratory, central nervous system, diabetes,
             psychosis or any other body system.

          4. History or presence of bronchial asthma.

          5. Use of enzyme-modifying drugs within 30 days prior to receiving the first dose of
             study medication.

          6. History of drug dependence, recent history of alcoholism or of moderate alcohol use.

          7. Smokers, who smoke more than or equal to 10 cigarettes per day or more than or equal
             to 20 biddies per day or those who can not refrain from smoking during study period.

          8. History of difficulty with donating blood or difficulty in accessibility of veins.
             Donation of blood (I unit: 350 mL/450 mL) within 90 days prior to receiving the first
             dose of study medication.

          9. A positive hepatitis screen (includes subtypes A, B, C &amp; E)

         10. A positive test result for HIV antibody and/or syphilis (RPR/VDRL).

         11. The receipt of an investigational product, or participation in a drug research study
             within a period of 90 days prior to the frst dose of study medication administration.

         12. Female volunteers demonstrating a positive pregnancy screen

         13. Female volunteers who are currently breast-feeding

         14. Female volunteers not willing to use contraception during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mayur Soni, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>BA Research India Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BA Research India Ltd</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujrat</state>
        <zip>380 054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2014</study_first_submitted>
  <study_first_submitted_qc>November 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2014</study_first_posted>
  <last_update_submitted>November 13, 2014</last_update_submitted>
  <last_update_submitted_qc>November 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

